Clinical Trial Update: IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating IBI363 as neoadjuvant therapy for resectable stage II-III non-small cell lung cancer is listed, with status not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IBI363

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Resectable Stage II-III Non-small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING